Wuhan Hiteck Biological
PUBLIC
STATUS
601-700
EMPLOYEES
300683
STOCK SYMBOL
$4.70
SHARE PRICE
(As of Thursday Closing)
Description
Wuhan Hiteck Biological Pharma Co Ltd is a biopharmaceutical manufacturing enterprise in China. The company is primarily engaged in the development, production and sale of biological products. Its product portfolio comprises rat nerve growth factor freeze-dried powder injection, injection of anti-hepatitis B transfer factor freeze-dried powder injection, thrombin and other chemicals. The company also has more than 20 kinds of products such as hepatitis B treatment drug op Heparin and hemostatic agent thrombin.
Primary Industry
Drug Discovery
Stock Exchange
SHE
Primary Office
- Hite Science and Technology Park
- Wuhan Economic Development Zone
- Wuhan, Hubei 430056
- China
+86 027 0000 0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Wuhan Hiteck Biological’s full profile, request a free trial.
Wuhan Hiteck Biological Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $3.69 - $5.56 | $486M | $4.68 | $0.15 | 1.25M | 103M |
Wuhan Hiteck Biological Financials Summary
|
In Thousands,
USD |
TTM
30-Jun-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 410,970 | 297,193 | 778,425 | |
| Revenue | 93,974 | 89,319 | 111,019 | 115,747 |
| EBITDA | 19,294 | 16,893 | 24,660 | 27,684 |
| Net Income | 15,166 | 14,230 | 21,070 | 23,579 |
| Total Assets | 311,055 | 313,324 | 292,364 | 149,662 |
| Total Debt | 26,313 | 29,793 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Wuhan Hiteck Biological Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Wuhan Hiteck Biological‘s full profile, request access.
Request full access to PitchBook